Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
1.
J Endocrinol Invest ; 2024 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-38850509

RESUMEN

PURPOSE: Polycystic ovary syndrome (PCOS) has been associated with Hashimoto's thyroiditis (HT) and 4 phenotypes have been described in this syndrome. The aim of this work was to investigate the frequency of anti-thyroid antibodies (TAb) and thyroid function in the 4 phenotypes of PCOS. PATIENTS: This study included 448 patients with PCOS: 260 (58.0%) with phenotype A, 119 (26.6%) with phenotype B, 38 (8.5%) with phenotype C and 31 (6.9%) with phenotype D. RESULTS: TAb positivity was detected in 90/448 patients (20.1%) and was statistically significant higher (p = 0.03) in the grouped phenotypes A-B (83/379, 21.9%) than in phenotypes C-D (7/69, 10.1%). Positive anti-thyroglobulin antibodies (TgAb) were detected in 74/448 (16.5%) patients and positive anti-thyroperoxidase antibodies (TPOAb) in 66/448 (14.7%) patients. Both TgAb and TPOAb positivity was higher but not statistically significant in phenotype A-B than phenotype C-D. High titer TgAb (> 100 UI/ml) frequency was significantly higher (p = 0.005) in grouped phenotypes A-B (39/379, 10.3%) than in phenotypes C-D (0/69, 0.0%), while no significant difference was observed for low titer TgAb (≤ 100 UI/ml). According to a binary logistic regression analysis hypothyroidism was significantly associated with TAb positivity (OR 4.19; CI 2.25-7.79; p < 0.01) but not with PCOS phenotype. Androgen profile was not associated with TAb positivity. CONCLUSION: A higher frequency of positive TAb and of high titer TgAb and TPOAb have been detected in PCOS women with phenotypes A and B, probably in relation to the greater imbalances between estrogen and progesterone levels present in these phenotypes.

2.
J Endocrinol Invest ; 47(4): 927-936, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-37907709

RESUMEN

AIM: To assess which parameters among hyperandrogenism (total testosterone-tT-or free androgen index-FAI), sex hormone binding globulin (SHBG) or body mass index (BMI) could better predict a worse metabolic profile in women with polycystic ovary syndrome (PCOS). METHODS: Five hundred and eighty-six women with PCOS and clinical or biochemical hyperandrogenism were included. Receiver Operating Characteristics (ROC) curves with tT, FAI, SHBG and BMI were performed for metabolic parameters and a cut-off with sensitivity and specificity was obtained for each parameter. The women were then divided into three groups and compared according to their BMI. RESULTS: Based on the ROC curves, tT proved not to be a good predictor of metabolic alterations. FAI and SHBG resulted to be good predictors of some markers of metabolic damage. The area under the curves (AUC) of SHBG were greater than those of FAI. SHBG levels affects the values of homeostasis model assessment of insulin resistance (HOMA-IR), fasting insulin, high density lipoproteins (HDL), low density lipoproteins (LDL), and total cholesterol also when corrected for BMI. However, the highest AUCs of the ROC curves were observed when BMI was used, which was significantly related to all the metabolic parameters analyzed. Dividing women according to their BMI, BMI between 25.00 and 30.00 kg/m2 had a worse metabolic profile but still in a normal range, while BMI ≥ 30 kg/m2 women had a significant metabolic derangement. DISCUSSION: BMI is a good predictor factor of metabolic changes in PCOS women at any age, and obesity is associated to the appearance of metabolic complications. Overweight and obese PCOS women should be addressed to perform a complete metabolic assessment.


Asunto(s)
Hiperandrogenismo , Resistencia a la Insulina , Síndrome del Ovario Poliquístico , Femenino , Humanos , Síndrome del Ovario Poliquístico/complicaciones , Hiperandrogenismo/complicaciones , Índice de Masa Corporal , Insulina/metabolismo , Testosterona , Obesidad/metabolismo
3.
J Endocrinol Invest ; 44(12): 2725-2733, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34089497

RESUMEN

PURPOSE: To assess the distribution of clinical features and metabolic abnormalities of polycystic ovary syndrome (PCOS) women according to their age. METHODS: Retrospective study on 602 women (mean age 23.9 ± 6.2 years), diagnosed according to International PCOS Network Guidelines criteria as having PCOS in a University-based Hospital. Anthropometric features, hormonal and metabolic parameters were measured and compared between the different age groups (group A ≤ 20 years; group B 21-30 years; group C > 30 years). RESULTS: Patients in group A were more often hyperandrogenic, while in group C hypertension, dyslipidemia, obesity, impaired fasting glucose, and insulin resistance (IR) were more prevalent. After adjusting for BMI, age correlated positively with sex hormone-binding globulin (SHBG), IR, total- and LDL-cholesterol, and negatively with DHEAS, insulin, and free androgen index (FAI). SHBG was significantly associated with IR and atherogenic dyslipidemia, while FAI levels were linked to hypertension, independently of other factors considered. Furthermore, the regression analysis showed a stronger relationship between BMI and metabolic outcomes, regardless of age. CONCLUSION: Polycystic ovarian syndrome (PCOS) phenotype changes with age. Clinical and biochemical hyperandrogenism are a major concern in young PCOS women, while metabolic burden tends to increase with aging. Some of the cardiovascular risk factors are dependent on FAI and SHBG levels, whereas BMI confirms its key role in the genesis of most of the metabolic sequelae in PCOS, independently of age.


Asunto(s)
Dislipidemias , Hiperandrogenismo , Hipertensión , Resistencia a la Insulina , Obesidad , Síndrome del Ovario Poliquístico , Adolescente , Adulto , Factores de Edad , Glucemia/metabolismo , Índice de Masa Corporal , Dislipidemias/diagnóstico , Dislipidemias/etiología , Dislipidemias/metabolismo , Femenino , Hormonas Esteroides Gonadales/análisis , Hormonas Esteroides Gonadales/metabolismo , Factores de Riesgo de Enfermedad Cardiaca , Humanos , Hiperandrogenismo/diagnóstico , Hiperandrogenismo/etiología , Hiperandrogenismo/metabolismo , Hipertensión/diagnóstico , Hipertensión/etiología , Hipertensión/metabolismo , Insulina/metabolismo , Italia/epidemiología , Obesidad/diagnóstico , Obesidad/etiología , Obesidad/metabolismo , Síndrome del Ovario Poliquístico/diagnóstico , Síndrome del Ovario Poliquístico/epidemiología , Síndrome del Ovario Poliquístico/metabolismo , Síndrome del Ovario Poliquístico/fisiopatología , Estudios Retrospectivos
4.
J Endocrinol Invest ; 44(5): 995-1000, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-32839937

RESUMEN

PURPOSE: During adolescence, PCOS features are supposed to be in evolution. Because of this, the diagnosis of PCOS in adolescence is often unclear and few studies have compared adolescent and adult PCOS phenotype distribution and features. The aim is to compare phenotypes in adolescents and young adults with PCOS. METHODS: 109 girls aged from 13 to 19 years were retrospectively studied. All patients had a gynecological age > 2 years. 63 patients were adolescents (3-5 years beyond menarche) while 46 patients were young adults (6-9 years beyond menarche). Diagnosis of different PCOS phenotypes (A, B, C, D) was made according to the Rotterdam criteria. Clinical data (menstrual cycles, BMI, presence of hirsutism), androgen circulating levels (total testosterone, androstenedione, dehydroepiandrosterone sulphate) and ovarian morphology by ultrasound were assessed. RESULTS: 109 patients presented PCOS according to the Rotterdam criteria. Phenotype A was by far the most common phenotype (73.4%) followed by phenotype B (21.1%). Only few patients had phenotype C (4.6%) or phenotype D (0.9%). When patients were divided in two groups (adolescent and young adult patients), no significant difference in prevalence and features of the different phenotypes was observed. CONCLUSION: In this cohort of adolescent and young adult women with PCOS, the progression of age does not change the prevalence and the features of main PCOS phenotypes. It suggests that the Rotterdam criteria might be used also in adolescents, at least in those with 2 or more years of gynecological age, for the diagnosis of PCOS.


Asunto(s)
Andrógenos/sangre , Hirsutismo , Menarquia/metabolismo , Ovario/diagnóstico por imagen , Síndrome del Ovario Poliquístico , Adolescente , Índice de Masa Corporal , Diagnóstico Precoz , Femenino , Hirsutismo/diagnóstico , Hirsutismo/metabolismo , Humanos , Italia/epidemiología , Fenotipo , Síndrome del Ovario Poliquístico/diagnóstico , Síndrome del Ovario Poliquístico/epidemiología , Síndrome del Ovario Poliquístico/metabolismo , Síndrome del Ovario Poliquístico/fisiopatología , Prevalencia , Ultrasonografía/métodos , Adulto Joven
5.
Gynecol Endocrinol ; 36(10): 938-940, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33021135

RESUMEN

Objective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.Methods: A 52-year-old woman with a 2 months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173 ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings.


Asunto(s)
Anticuerpos Heterófilos , Errores Diagnósticos , Gonadotropinas/sangre , Menopausia/sangre , Animales , Femenino , Cabras/inmunología , Humanos , Persona de Mediana Edad
6.
Eur J Contracept Reprod Health Care ; 25(3): 231-232, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32436739

RESUMEN

Purpose: The Italian Society of Contraception identified as one of its priorities the need to give recommendations on management of contraception during Coronavirus-Covid 19 pandemiaMaterials and methods: A concise communication was produced which summarises in an easy-to-read format suitable for clinicians the management of the different contraceptives mostly used. Information how to manage contraception in different conditions is presented.Results: Women may, in general, continue to use either intrauterine and or hormonal contraceptives. The use of condom should be added to any hormonal contraceptive, when the contraceptive efficacy is reduced or when women stop the contraceptive method.Conclusion: At the present time, during the Coronavirus-Covid 19 pandemia, no data contraindicate the use of intrauterine or hormonal contraceptives. Conversely the use of an appropriate contraception is advocate to prevent unintended pregnancies.


Asunto(s)
Anticoncepción/normas , Infecciones por Coronavirus , Coronavirus , Pandemias , Neumonía Viral , Guías de Práctica Clínica como Asunto , COVID-19 , Anticonceptivos Femeninos/normas , Femenino , Humanos , Comunicación Interdisciplinaria , Italia , Sociedades Médicas/normas
7.
Climacteric ; 23(1): 3-8, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31352836

RESUMEN

Premature ovarian insufficiency (POI) is probably one of the most devastating diagnoses for women of reproductive age. The major implications for fertility, climacteric symptoms, and quality of life, the great impact of long-term consequences such as bone loss and cardiovascular health, and the lack of a coherent and shared clinical approach make the choice for the right hormonal therapy challenging. In this review we propose an integrated and patient-based hormonal approach for women with POI, from puberty to late reproductive age.


Asunto(s)
Anticonceptivos Orales Combinados/uso terapéutico , Terapia de Reemplazo de Hormonas/métodos , Insuficiencia Ovárica Primaria/tratamiento farmacológico , Adulto , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Niño , Femenino , Humanos , Atención Dirigida al Paciente/métodos , Insuficiencia Ovárica Primaria/complicaciones , Pubertad/efectos de los fármacos , Calidad de Vida , Adulto Joven
8.
Minerva Ginecol ; 64(6): 539-49, 2012 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-23232538

RESUMEN

The venous thromboembolism (VTE) is a rare event during childbearing age and during the assumption of combined oral contraceptive. The absolute risk of VTE in users of combined oral contraceptives is 20-30 per 100000 women years. A number of case-control studies published in recent years have shown an apparent increase in the risk of VTE among users of oral contraceptives (OCs) containing desogestrel, gestodene, drospirenone and cyproterone, relative to the use of levonorgestrel. The data derived from these recent studies is of borderline statistical significance because any important factors are not considered to evaluate the real correlation between the assumption of OCs and risk of venous thromboembolism. Among the factors that should be considered, there are: EE dose, duration of use, coexistance of other risk factors of venous thromboembolism (age, BMI, familiarity, surgical interventions) and other prescription bias. The lack of these factors is likely to contribute to the increased risk of venous thromboembolism observed in users of third-generation OCs when compared to that in users of second-generation OCs. To date, because of the inadequacy of epidemiological studies, the data about the correlation between OCs and TVE, are not conclusive and it will be necessary to carry out other studies to clarify this debating point, definitively.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Trombofilia/inducido químicamente , Tromboembolia Venosa/epidemiología , Resistencia a la Proteína C Activada/inducido químicamente , Adolescente , Adulto , Biomarcadores , Estudios de Casos y Controles , Ensayos Clínicos como Asunto , Comorbilidad , Anticonceptivos Orales/química , Anticonceptivos Orales Combinados/efectos adversos , Anticonceptivos Orales Combinados/química , Anticonceptivos Hormonales Orales/efectos adversos , Anticonceptivos Hormonales Orales/química , Femenino , Humanos , Persona de Mediana Edad , Obesidad/epidemiología , Vigilancia de Productos Comercializados , Factores de Riesgo , Globulina de Unión a Hormona Sexual/análisis , Fumar/epidemiología , Trombofilia/sangre , Tromboembolia Venosa/etiología , Adulto Joven
9.
Eur J Contracept Reprod Health Care ; 13(2): 153-7, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18465477

RESUMEN

OBJECTIVES: Perceptions of menstruation vary according to culture and religion. This study addresses attitudes of Italian women towards changes in menstrual frequency induced by oral contraceptives (OCs) administered in an extended regimen. METHODS: Three-hundred-and-fifty healthy women of reproductive age were enrolled in three test areas in Italy. Participants completed a standardized questionnaire. One-hundred-and-ten men, aged 21-54 years, accompanying their partners to the gynaecological consultation were also given a questionnaire to get to know their opinion about the extended use of OCs by their partner. RESULTS: Only 32% of Italian women prefer to bleed monthly. The preferred frequencies in all age groups were 3-monthly (23.7%) or never (26%). Of the OC-users, 57.2% preferred to bleed less than once a month: 26% wished to bleed every 3 months, and 21.2% once a year. Among men, 58.1% considered an extended OC regimen to be acceptable. CONCLUSIONS: About 60% of Italian women with spontaneous or OC-driven cycles prefer to bleed less than monthly. This fact should be kept in mind by physicians when prescribing OCs.


Asunto(s)
Amenorrea/inducido químicamente , Actitud Frente a la Salud , Anticonceptivos Orales/administración & dosificación , Menstruación , Adolescente , Adulto , Esquema de Medicación , Femenino , Humanos , Italia , Menstruación/efectos de los fármacos , Persona de Mediana Edad
10.
Hum Reprod ; 22(9): 2501-8, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17635847

RESUMEN

BACKGROUND: The introduction of transvaginal approach in ultrasound (US) has enabled the accurate evaluation of the structure of the ovary and stroma. Stroma represents an acknowledged US marker for polycystic ovary syndrome (PCOS). The proportion revealed between the stroma and the ovary surface in the median section (S/A ratio) had been indicated as a reliable marker for hyperandrogenism. In order to verify the feasibility of this determination in routine use and to confirm the efficacy of S/A ratio in predicting hyperandrogenism in PCOS, a multicentric study was performed in association with five Italian research groups. METHODS: A total of 418 subjects of fertile age presenting oligomenorrhoea or secondary amenorrhoea, enlarged ovaries measuring >10 cm(3) and/or >12 follicles measuring 2-9 mm in diameter took part in the study. Clinical, US and hormonal evaluations were performed in the early follicular phase or on random days in amenorrhoeic subjects. US assessment included ovarian volume, follicle number, ovarian and stroma area in median section. The hormonal study included a baseline plasma determination of LH, FSH, estradiol (E(2)), androstenedione (A), testosterone (T), dehydroepiandrosteronesulphate, 17-hydroxy-progesterone, sex hormone-binding globulin and prolactin. Correlations and receiver operator curves were used in statistical analysis of data. RESULTS: S/A was found to be the best significant predictor of elevated A and T levels. In order to ascertain significant cut-off values in relation to A and T levels Youden indexes were calculated and indicated 0.32 as the best cut-off for the S/A ratio. CONCLUSIONS: This work underlines the importance of stroma measure in improving US diagnosis of PCOS and suggest that this parameter may be used in routine clinical practice. In fact, multicentre study demonstrated the easy feasibility of such procedure without need of sophisticated machines or intensive training for operators.


Asunto(s)
Andrógenos/sangre , Endosonografía/métodos , Hiperandrogenismo/diagnóstico , Ovario/ultraestructura , Síndrome del Ovario Poliquístico/diagnóstico por imagen , Adolescente , Adulto , Femenino , Humanos , Hiperandrogenismo/etiología , Italia , Síndrome del Ovario Poliquístico/complicaciones , Pronóstico
11.
J Clin Endocrinol Metab ; 91(9): 3451-6, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16822826

RESUMEN

CONTEXT: Because many women with 21-hydroxylase (21-OH)-deficient nonclassic adrenal hyperplasia (NCAH) carry at least one allele affected by a severe mutation of CYP21, they are at risk for giving birth to infants with classic adrenal hyperplasia (CAH). OBJECTIVE: Our objective was to determine the frequency of CAH and NCAH infants born to mothers with 21-OH-deficient NCAH. DESIGN AND SETTING: We conducted an international multicenter retrospective/prospective study. PATIENTS AND METHODS: The outcome of 203 pregnancies among 101 women with 21-OH-deficient NCAH was reviewed. The diagnosis of 21-OH-deficient NCAH was established by a basal or post-ACTH-stimulation 17-hydroxyprogesterone level of more than 10 ng/ml (30.3 nmol/liter). When possible, genotype analyses were performed to confirm CAH or NCAH in the offspring. RESULTS: Of the 203 pregnancies, 138 (68%) occurred before the mother's diagnosis of NCAH and 65 (32%) after the diagnosis. Spontaneous miscarriages occurred in 35 of 138 pregnancies (25.4%) before the maternal diagnosis of NCAH, and in only four of 65 pregnancies (6.2%) after the diagnosis (P < 0.002). Four (2.5%; 95% confidence interval, 0.7-6.2%) of the 162 live births were diagnosed with CAH. To date, 24 (14.8%; 95% confidence interval, 9.0-20.6%) children, 13 girls and 11 boys, have been diagnosed with NCAH. The distribution of NCAH children and their mothers varied significantly by ethnicity (P < 0.0001, for both). CONCLUSIONS: The risk of a mother with 21-OH-deficient NCAH for giving birth to a child affected with CAH is 2.5%; at least 14.8% of children born to these mothers have NCAH.


Asunto(s)
Hiperplasia Suprarrenal Congénita/genética , Esteroide 21-Hidroxilasa/genética , Hiperplasia Suprarrenal Congénita/enzimología , Hiperplasia Suprarrenal Congénita/epidemiología , Adulto , Preescolar , Femenino , Genotipo , Humanos , Lactante , Recién Nacido , Masculino , Embarazo , Prevalencia , Estudios Prospectivos , Estudios Retrospectivos
12.
Climacteric ; 7(3): 238-54, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15669548

RESUMEN

An experts' meeting on the 'Role of progestins with partial antiandrogenic effects' was held in Berlin from January 19 to 22, 2001. The meeting was chaired by Dr R. Sitruk-Ware (New York, USA) and participants included Ms F. Fruzzetti (Pisa, Italy), J. Hanker (Trier, Germany), J. Huber (Vienna, Austria), F. Husmann (Bad Sassendorf, Germany), S. O. Skouby (Copenhagen, Denmark), J. H. H. Thijssen (Utrecht, The Netherlands), and R. Druckmann (Nice, France). The present paper reports the conclusions of the meeting. However, the publication of the Women's Health Initiative study, which appeared after the meeting, led to additional comments and revisions.


Asunto(s)
Antagonistas de Andrógenos , Terapia de Reemplazo de Estrógeno , Progestinas , Femenino , Humanos
14.
Contraception ; 63(6): 303-7, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11672551

RESUMEN

The effects of a 24-day regimen containing 15 microg ethinyl estradiol (EE) plus 60 microg gestodene on cycle control and on hemostasis, were evaluated in 58 healthy women (age 19-47 years). All women received the pill for 12 months. Withdrawal bleeding at every cycle during the tablet-free interval was experienced by 84.5% of the women. The overall incidence of irregular bleedings was 19.3%. Hemostasis was evaluated in 20 women. No changes in plasma fibrinogen concentrations, nor in prothrombin fragment F1+2 were observed. A slight increase in thrombin-antithrombin III complexes was observed after 6 and 12 months of oral contraceptive use. Antithrombin III activity significantly increased after one-year of pill intake. The concentrations of tissue plasminogen activator and plasminogen activator inhibitor, both antigen and activity, did not change. These results show that very low doses of EE, such as 15 microg, do not impair hemostasis in healthy females. However, the reduction for the EE dose is responsible of some of the effects on cycle control.


Asunto(s)
Anticonceptivos Sintéticos Orales/administración & dosificación , Anticonceptivos Sintéticos Orales/efectos adversos , Etinilestradiol/administración & dosificación , Etinilestradiol/efectos adversos , Hemostasis/efectos de los fármacos , Hemostasis/fisiología , Ciclo Menstrual/efectos de los fármacos , Ciclo Menstrual/fisiología , Norpregnenos/administración & dosificación , Norpregnenos/efectos adversos , Adolescente , Adulto , Análisis de Varianza , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Factores de Tiempo , Tiempo de Coagulación de la Sangre Total
15.
J Steroid Biochem Mol Biol ; 78(3): 247-52, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11595505

RESUMEN

OBJECTIVE: To evaluate adrenal steroid hormone secretion in response to corticotropin-releasing factor (CRF) or to adrenocorticotropin hormone in women with hypothalamic amenorrhea. DESIGN: Controlled clinical study. SETTING: Department of Reproductive Medicine and Child Development, Section of Gynecology and Obstetrics, University of Pisa, Italy. PATIENT(S): Fifteen women with hypothalamic amenorrhea were enrolled in the study. Eight normal cycling women were used as control group. INTERVENTION(S): Blood samples were collected before and after an injection of ovine CRF (0.1 microg/kg iv bolus) or after synthetic ACTH (0.25 mg iv). MAIN OUTCOME MEASURE(S): Plasma levels of ACTH, 17-hydroxypregnenolone (17OHPe), progesterone (P), dehydroepiandrosterone (DHEA), 17-hydroxyprogesterone (17OHP), cortisol (F), 11-deoxycortisol (S) and androstenedione (A). RESULT(S): Basal plasma concentrations of ACTH, cortisol, 11-deoxycortisol, DHEA and 17OHPe were significantly higher in patients than in controls, whereas plasma levels of progesterone and 17-OHP were significantly lower in patients than in controls. In amenorrheic women the ratio of 17-OHPe/DHEA, of 17-OHPe/17-OHP and of 11-deoxycortisol/cortisol were significantly higher than in controls, while a significant reduction in the ratio of 17-OHP/androstenedione, of 17-OHP/11-deoxycortisol was obtained. In response to corticotropin-releasing factor test, plasma levels of ACTH, cortisol, 17-OHP, 11-deoxycortisol, DHEA and androstenedione were significantly lower in patients than in controls. In response to adrenocorticotropin hormone, plasma levels of 17-OHP, androstenedione and androstenedione/cortisol were significantly higher in patients than in controls. CONCLUSIONS: Patients suffering for hypothalamic amenorrhea showed an increased activation of hypothalamus-pituitary-adrenal (HPA) axis, as shown by the higher basal levels and by augmented adrenal hormone response to corticotropin-releasing factor administration. These data suggest a possible derangement of adrenal androgen enzymatic pathway.


Asunto(s)
Corticoesteroides/metabolismo , Amenorrea/fisiopatología , Hormona Liberadora de Corticotropina , Enfermedades Hipotalámicas/fisiopatología , 17-alfa-Hidroxipregnenolona/sangre , 17-alfa-Hidroxiprogesterona/sangre , Adolescente , Corticoesteroides/sangre , Hormona Adrenocorticotrópica/sangre , Adulto , Amenorrea/diagnóstico , Amenorrea/etiología , Andrógenos/sangre , Andrógenos/metabolismo , Estudios de Casos y Controles , Cortodoxona/sangre , Deshidroepiandrosterona/sangre , Femenino , Humanos , Hidrocortisona/sangre , Enfermedades Hipotalámicas/complicaciones , Enfermedades Hipotalámicas/diagnóstico , Sistema Hipotálamo-Hipofisario/fisiopatología , Sistema Hipófiso-Suprarrenal/fisiopatología , Esteroides/sangre
16.
Am J Obstet Gynecol ; 183(6): 1468-74, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11120512

RESUMEN

OBJECTIVE: Our aim was to determine whether the clinical features of 21-hydroxylase-deficient nonclassic adrenal hyperplasia are correlated with either age at symptom onset or age at presentation, or both, and with the degree of adrenocortical abnormality. STUDY DESIGN: In a multicenter cohort design 220 women with nonclassic adrenal hyperplasia, with a basal or adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone level >30.3 nmol/L, were studied, either prospectively (n = 39) or retrospectively (n = 181). Patients were stratified by age of presentation into 5 groups: (1) <10 years (n = 25), (2) 10 to 19 years (n = 64), (3) 20 to 29 years (n = 83), (4) 30 to 39 years (n = 30), and (5) 40 to 49 years (n = 16). Two patients >50 years old were excluded from the analysis because of age. RESULTS: Ninety-two percent of patients <10 years old had premature pubarche at presentation, whereas clitoromegaly and acne were each present in only 20% of these younger subjects. With only patients > or =10 years old considered, presenting clinical features included hirsutism (59%), oligomenorrhea (54%), acne (33%), infertility (13%), clitoromegaly (10%), alopecia (8%), primary amenorrhea (4%), and premature pubarche (4%). Among the patients >/=10 years old, the prevalence but not the degree of hirsutism increased significantly with age. Basal levels of 17-hydroxyprogesterone in adolescents were significantly higher than the levels found either in children (<10 years old) or women 40 to 49 years old (P <.01 and P <.03, respectively), although no difference was noted in the stimulated 17-hydroxyprogesterone levels between age groups. The adrenocorticotropic hormone-stimulated levels but not the basal levels of 17-hydroxyprogesterone were significantly higher in patients with clitoromegaly than in women without clitoromegaly. Alternatively, there were no differences in either basal or stimulated 17-hydroxyprogesterone levels between patients with and those without hirsutism, acne, or alopecia. CONCLUSION: In children <10 years old the most common presenting complaint was premature pubarche, whereas hirsutism and oligomenorrhea were more common in older patients. The prevalence of hirsutism increased with age, suggesting the progressive nature of nonclassic adrenal hyperplasia. Furthermore, the adrenocorticotropic hormone-stimulated levels of 17-hydroxyprogesterone were higher in patients with clitoromegaly, which suggests that the degree of adrenocortical dysfunction in nonclassic adrenal hyperplasia determines, at least in part, the clinical presentation.


Asunto(s)
Hiperplasia Suprarrenal Congénita/enzimología , 17-alfa-Hidroxiprogesterona/sangre , Adolescente , Hormona Adrenocorticotrópica , Adulto , Envejecimiento/fisiología , Niño , Preescolar , Clítoris , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Hirsutismo/etiología , Humanos , Persona de Mediana Edad , Oligomenorrea/etiología , Estudios Prospectivos , Pubertad Precoz/etiología , Estudios Retrospectivos , Enfermedades de la Vulva/sangre , Enfermedades de la Vulva/etiología
17.
Mol Genet Metab ; 71(3): 527-34, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11073721

RESUMEN

Characteristic presentation of nonclassical adrenal hyperplasia (NCAH) due to 21-hydroxylase deficiency was compared between women carrying a severe and a mild CYP21 mutation (Group 1, N = 26) versus homozygotes for mild mutations (Group 2, N = 8). The diagnosis was based on elevated ACTH-stimulated 17OH-progesterone (17OHP). Genotyping for 10 mutations was performed by PCR-based techniques. Jewish patients predominated among Group 2 (25% vs 11.5% in Group 1); however, 85% of all patients were non-Jewish Caucasians. Average age of presentation was 23-25 years, and did not differ between groups. Hirsutism, and to a lesser extent oligomenorrhea and acne, were more prevalent among Group 1 women. There was a trend to higher basal 17OHP among Group 1 patients (mean +/- SEM; 1354+/-323 vs 714+/-129 ng/dl, P< or =0.25). The lack of significant difference was perhaps due to the relatively few homozygotes for 2 mild mutations (24%). V281L was carried on approximately 48% of all alleles, and about 16% carried either P30L or P453S. Approximately 38% of alleles and 77% of patients carried a classic mutation. These data have important implications for genetic counseling. In summary, we describe differences in clinical, hormonal, and genetic characteristics among a multiethnic group of females with NCAH.


Asunto(s)
Hiperplasia Suprarrenal Congénita/genética , Esteroide 21-Hidroxilasa/genética , 17-alfa-Hidroxiprogesterona/sangre , Acné Vulgar/complicaciones , Adolescente , Hiperplasia Suprarrenal Congénita/complicaciones , Hiperplasia Suprarrenal Congénita/enzimología , Adulto , Alelos , Sustitución de Aminoácidos , Índice de Masa Corporal , Niño , Femenino , Frecuencia de los Genes , Genotipo , Hirsutismo/complicaciones , Humanos , Persona de Mediana Edad , Mutación , Oligomenorrea/complicaciones , Fenotipo
18.
Eur J Contracept Reprod Health Care ; 4(3): 113-8, 1999 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10574636

RESUMEN

The concurret use of smoking and oral contraceptives affects the hemostatic balance, thereby inducing a thrombophilic state. In order to clarify the effects of this association on the hemostatic system, the possible changes in the markers of activation of coagulation (thrombin-antithrombin III complexes and prothrombin fragment F1+2) were evaluated in 35 women given a third-generation oral contraceptive for 6 months; 13 of these women (37.1%) were mild or moderate smokers. No differences were found in basal levels of the coagulation and fibrinolytic parameters between smokers and non-smokers. During oral contraceptive administration, both F1+2 fragment and thrombin-antithrombin III complex concentrations significantly increased both in smokers and in non-smokers (p < 0.01). Fibrinogen plasma levels increased in both groups (p < 0.01). Antithrombin III activity was reduced in both groups during treatment, but the difference was significant only in smokers (p < 0.05). Although the sample size of smokers was too small to draw definitive conclusions, present results appeared to confirm previous data about the effect of the concurrent use of smoking and oral contraceptives on antithrombin III levels, but did not demonstrate any additional effect of moderate smoking on the activation of the clotting system induced by this oral contraceptive preparation.


Asunto(s)
Antitrombina III/análisis , Coagulación Sanguínea/efectos de los fármacos , Desogestrel/administración & dosificación , Etinilestradiol/administración & dosificación , Fibrinógeno/análisis , Protrombina/análisis , Fumar/efectos adversos , Adolescente , Adulto , Análisis de Varianza , Coagulación Sanguínea/fisiología , Anticonceptivos Orales Combinados/administración & dosificación , Femenino , Humanos , Valores de Referencia , Sensibilidad y Especificidad
19.
Thromb Haemost ; 82(3): 1164-70, 1999 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10494782

RESUMEN

Because of the association of oral contraceptives (OC) and cigarette smoking with an increased thrombotic risk, we evaluated thromboxane (TX) and prostacyclin urinary (u) metabolites, as in vivo indices of platelet-vessel wall interactions, in women assigned to third generation OC. Twenty-eight women (15 smokers) underwent a 6-month trial of 30 microg ethinylestradiol plus 0.150 mg desogestrel. Cotinine plasma levels were elevated only in persons classified as smokers and serum TXB2 determination confirmed the absence of cyclooxygenase inhibition throughout the study. u-TXB2 and 11-dehydro-TXB2 were higher in smokers than in non-smokers. OC decreased u-11-dehydro-TXB2 both in smokers (from (pg/micromol creatinine) 35.1+/-6.9 to 15.8+/-2.8; P<0.025) and non-smokers (from 31.7+/-9.8 to 20.6+/-4.8, P = N.S.). u-6-keto-prostaglandin(PG)F1alpha excretion, also higher in smokers compared to non-smokers, was also reduced after OC in smokers (from (pg/micromol creatinine) 24.3+/-5.2 to 14.8+/-2.3; P<0.05). Smokers also had a trend to higher u-2,3-dinor-6-keto-PGF1alpha, marginally reduced by OC. Thus, the OC regimen used here improves - if anything - platelet vessel wall interactions as assessed by prostanoid production in vivo. The prothrombotic tendency associated with the use of OC in smokers does not appear to be mediated by changes in platelet-vessel wall interactions.


Asunto(s)
Plaquetas/efectos de los fármacos , Vasos Sanguíneos/efectos de los fármacos , Anticonceptivos Orales/efectos adversos , 6-Cetoprostaglandina F1 alfa/orina , Adolescente , Adulto , Plaquetas/fisiología , Vasos Sanguíneos/fisiología , Femenino , Humanos , Factores de Riesgo , Fumar/efectos adversos , Trombosis/etiología , Tromboxano B2/análogos & derivados , Tromboxano B2/orina
20.
Am J Obstet Gynecol ; 180(6 Pt 2): S369-74, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10368523

RESUMEN

This review addresses current knowledge of the effects of lower dose oral contraceptives (containing 35, 30, or 20 micrograms of ethinyl estradiol) on hemostasis in smoking and nonsmoking women. Evidence suggests that formulations containing 30 and 35 micrograms ethinyl estradiol induce a significant activation of coagulation, whereas oral contraceptive preparations with 20 micrograms ethinyl estradiol appear to have a negligible effect or no effect. In nonsmokers who take oral contraceptives any procoagulatory effects that may occur are counterbalanced by fibrinolytic effects. In smokers, however, compensatory fibrinolytic effects to offset the procoagulatory effects seen with 30-micrograms ethinyl estradiol oral contraceptive formulations are absent, shifting the hemostatic profile toward a hypercoagulable state. This suggests that a formulation with the lowest dose of ethinyl estradiol may be most suitable for smokers who wish to use this form of contraception.


PIP: This review addresses current knowledge of the effects of lower-dose oral contraceptives (OCs) (containing 35, 30, or 20 mcg of ethinyl estradiol) on hemostasis in smoking and nonsmoking women. Data showed that the OCs containing 30-35 mcg ethinyl estradiol influence a significant activation of coagulation parameters compared to the 20-mcg formulations, which appear to have little or no procoagulatory effect. However, procoagulatory effects of these OCs showed to be counterbalanced by the compensatory anticoagulation effects within the fibrinolytic system. This would indicate that most healthy women taking lower-dose OCs, particularly those containing 20 mcg ethinyl estradiol, are not at increased risk for thromboembolic disease. However, this compensatory activity of the fibrinolytic system does not occur in women who both smoke and use OCs. Studies documented that simultaneous smoking and OC use could lead to hypercoagulation. This suggests that OCs with the lowest effective dose of ethinyl estradiol are the best contraceptives for smokers.


Asunto(s)
Anticonceptivos Orales/efectos adversos , Hemostasis/fisiología , Fumar/efectos adversos , Coagulación Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Etinilestradiol/administración & dosificación , Etinilestradiol/efectos adversos , Femenino , Fibrinólisis/efectos de los fármacos , Humanos , Valores de Referencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...